<DOC>
	<DOCNO>NCT00043329</DOCNO>
	<brief_summary>The purpose study establish registry child severe , malignant osteopetrosis treat Actimmune ( IFN-g 1b Interferon gamma-1b ) monitor effect IFN-g 1b prevent progression disease follow safety patient receive long-term basis . In addition , evaluation possible effect Actimmune therapy humoral response normal childhood vaccination patient population examined.Interferon gamma substance body make naturally .</brief_summary>
	<brief_title>Post Marketing Surveillance Study Actimmune Patients With Severe , Malignant Osteopetrosis</brief_title>
	<detailed_description>It make white blood cell appear involved regulate body 's ability fight infection . Actimmune synthetic form Interferon gamma similar normally make white blood cell . IFN-g 1b ( ActimmuneÂ® ) currently approve United States Food Drug Administration ( FDA ) treatment patient chronic granulomatous disease ( CGD ) reduce frequency severity serious infection . It also approve patient severe , malignant osteopetrosis delay time disease progression . In research trial , IFN-g 1b give 2,000 patient diseases CGD , osteopetrosis , atopic dermatitis , pulmonary fibrosis , atypical mycobacteria various cancer .</detailed_description>
	<mesh_term>Osteopetrosis</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Male female Diagnosis severe , malignant osteopetrosis Currently receive plan initiate therapy Actimmune ( Interferon gamma1b ) Willing attend followup appointment every 6 month follow enrollment study , clinically indicate</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Registry</keyword>
	<keyword>Actimmune</keyword>
	<keyword>osteopetrosis</keyword>
</DOC>